Navigation Links
NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
Date:10/9/2007

BEDMINSTER, N.J., Oct. 9 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that by mutual agreement it has ended its collaboration with AstraZeneca to discover and develop drugs targeting metabotropic glutamate receptors (mGluRs). AstraZeneca has agreed to pay NPS $30 million to acquire NPS's assets related to the companies' research collaboration to discover and develop the compounds. NPS intends to use the proceeds to support further development of its late-stage product pipeline.

The two companies have been collaborating since March 2001 to discover and develop compounds that are active at these receptors and have identified several drug candidates currently in preclinical and Phase 1 studies. Under the terms of the agreement, NPS will no longer provide research support for or maintain interests in any drugs discovered, developed and commercialized under this program.

Dr. Tony Coles, president and CEO of NPS, stated, "Monetizing our interests in the mGluR program at this time enables us to create greater near-term value for NPS shareholders. This strategic move creates investment flexibility for NPS and enables us to use the monies from this deal, the previously announced Nycomed GATTEX deal and the approximately $10 million in savings over the next two years from this transaction to support the further development of our late-stage pipeline products, PREOS and GATTEX, in specialty indications. We have had a very productive collaboration with AstraZeneca and wish them continued success with this program."

About NPS Pharmaceuticals

NPS discovers and develops small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development backed by a strong discovery research effort. Additional information is available on the company's website, http://www.npsp.com.

Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of October 9, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended June 30, 2007.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Heart disease in the newborn is related to maternal malnutrition
2. Individuals with sleep related breathing disorders more prone to heart disease
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Dampness related to asthma
6. Allergies are related to mothers menses
7. Genetic disorder related with sleep patterns
8. Energy intake directly related to portion size
9. Treatment for cholesterol-related illnesses likely with the discovery of receptor in mice
10. Age-Related Macular Degeneration - Risk Factors
11. New Drug Shows Significant Improvement In HIV-related Heart Condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the leading provider ... announced today the launch of a redesigned corporate website, 800response.com . ... responsive design, and an enhanced search directory for businesses and advertising agencies to ...
(Date:8/18/2017)... ... ... Our Imaginations: The Infinite God”: shows the importance of God in living a happy ... author, Mark Lawrence, born in Michigan, the author has lived in various communities and ... of God is that I have to be more mindful of feminine qualities to ...
(Date:8/18/2017)... ... ... “Prompted By Love”: a love story thrown into doubt by untimely news. “Prompted ... Nettles has devoted her life to ministry since the age of 12 when she ... however, not fulfilled until 2014 when "The Color of Roses" was published. After ...
(Date:8/17/2017)... ... August 17, 2017 , ... Shared ... and considered extremely effective, very effective, or effective by 85% of respondents, according ... NEJM Catalyst Insights Reports are based on surveys of the NEJM Catalyst Insights ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... LOS ANGELES , Aug. 17, 2017 ... by CBMJ – Canna Broadcast Media, today reveals its leading ... that Isodiol International Inc., a global cannabis innovator specializing in ... platinum sponsor of the conference. MassRoots, Rambridge™ and The Green ... Signal Bay Inc. and Namaste Vapes™ as silver sponsors. ...
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/10/2017)... 10, 2017  Physical Rehabilitation Network (PRN), acquired the long-standing ... Lakewood, Colorado . The reputable clinic will continue to ... DPT with his staff of four clinicians. Lipkin received his ... brings over 10 years of experience with a strong background ... PT marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology: